# India Sickle Cell Anaemia Market

> India Sickle Cell Anaemia Market Research Report Information by Type (Sickle Cell Anemia (SS), Sickle Hemoglobin-C Disease (SC), Sickle Beta-Plus Thalassemia, and Sickle Beta-Zero Thalassemia) by Diagnosis & Treatment Type [(Diagnosis (Instruments and Reagents and kits), Treatment, (Pharmacotherapy, (Oral and Parenteral), Blood Transfusion, and Bone Marrow Transplant)] - Forecast till 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 12.22%
- **2024:** $ 0.26 Billion
- **2025:** $ 0.29 Billion
- **2035:** $ 0.92 Billion
- **Key Players:** Bristol Myers Squibb (IN), Novartis (IN), Pfizer (IN), Roche (IN), Amgen (IN), Boehringer Ingelheim (IN), Sanofi (IN), Celgene (IN), GSK (IN)

**Report ID:** MRFR/LS/20445-CR · **Pages:** 76 · **Author:** Nidhi Mandole & Rahul Gotadki · **Last Updated:** April 02, 2026

**URL:** https://www.marketresearchfuture.com/reports/india-sickle-cell-anaemia-market-22045

---

## Market Summary

## **India Sickle Cell Anaemia Market Overview**

As per MRFR analysis, the India Sickle Cell Anaemia Market Size was estimated at 0.26 (USD Billion) in 2024. The India Sickle Cell Anaemia Market Industry is expected to grow from 0.30 (USD Billion) in 2025 to 1.04 (USD Billion) till 2034, at a CAGR (growth rate) is expected to be around 14.68% during the forecast period (2025 - 2034). The growing government support and policies associated with sickle cell Anaemia in India and increased prevalence of sickle cell among India increases the demand for drug treatment are driving market growth.

Source: Secondary Research, Primary Research, _Market Research Future_ Database, and Analyst Review

## **India Sickle Cell Anaemia Market Trends**

### **The growing government support and policies associated with sickle cell Anaemia in India boosts market growth**

Government support and policies associated with sickle cell anaemia (SCD) in India provide several benefits for individuals affected by the disease including improved access to healthcare, subsidized treatment and medication, and awareness and education programs. Moreover, it also includes inclusion in public health programs and advocacy and policy development. There are several initiatives which Indian government has taken in recent years which bolstered the growth of sickle cell anaemia. For instance.

In July 2023, The National Sickle Cell Anaemia Elimination Mission was launched in Madhya Pradesh and aims to screen approximately 70 million people under 40 years of age in the next three years. The objective of the National Sickle Cell Anaemia Elimination Mission is to eliminate sickle cell anemia by 2047.

Furthermore, overall, government support and policies associated with sickle cell anemia in India play a crucial role in improving healthcare access, reducing financial barriers, raising awareness, and advocating for the needs of affected individuals and their families. These initiatives contribute to better outcomes and quality of life for those living with the disease.

## **India Sickle Cell Anaemia Market Segment Insights**

### **India Sickle Cell Anaemia Type Insights**

The India sickle cell anaemia market segmentation, based on type, includes Sickle Cell Anemia (SS), Sickle Hemoglobin-C Disease (SC), Sickle Beta-Plus Thalassemia, and Sickle Beta-Zero Thalassemia. The sickle cell anemia (SS) segment held the majority share in 2022 in the India sickle cell Anaemia market revenue. This is due to the increasing disease awareness, rise in complications associated with sickle cell anemia, such as hemolysis and vaco-occlusive crisis(voc).

**INDIA SICKLE CELL ANAEMIA MARKET SIZE, BY TYPE, 2022 & 2032 (USD Billion)**

Source: Secondary Research, Primary Research, _Market Research Future_ Database, and Analyst Review

### **India Sickle Cell Anaemia Diagnosis & Treatment Type Insights**

The India sickle cell anaemia market segmentation is based on product that include diagnosis & treatment type. Furter, the diagnosis segment is further segmented into instruments and reagents and kits. Furthermore, the treatment segment is further bifurcated into pharmacotherapy, blood transfusion, and [bone marrow transplant](../../../reports/bone-marrow-transplant-market-21336). The pharmacotherapy segment has dominated the market in 2022 and is projected to be the fastest-growing segment during the forecast period, 2025-2034. This is attributed to the prevalence of sickle beta-zero thalassemia, a severe form of thalassemia and rising healthcare expenditure.

## **India Sickle Cell Anaemia Key Market Players & Competitive Insights**

The India sickle cell anaemia market is characterized by the presence of many regional, and local vendors. Developments in the healthcare industry and growing research and development make the sickle cell Anaemia market lucrative. To expand their reach and optimize their operational costs, the major players focus on obtaining regulatory authorizations from government agencies for their products and emphasize acquisitions and product launches to gain a substantial market share. The market comprises tier-1, tier-2, and local players. The tier-1 and tier-2 players have reach across the globe with diverse product portfolios.

Companies such as Cipla Ltd (India), United Biotech Pvt Ltd. (India), Neon (India), and Novartis AG (Switzerland) dominate the India sickle cell anaemia market due to product differentiation, financial stability, strategic developments, and diversified regional presence. The players are focused on investing in research and development. Furthermore, they adopt strategic growth initiatives, such as expansion, product launches, joint ventures, and partnerships, to strengthen their market position and capture a large customer base.

One of the primary business strategies adopted by manufacturers in the India sickle cell anaemia industry to benefit clients and expand the sickle cell anaemia market sector is to manufacture locally to reduce operating costs.

Cipla Ltd. (Cipla) is a global pharmaceutical company with a portfolio of over 1,000 products across a wide range of therapeutic categories with one quality standard globally. Its products are available in more than 50 dosage forms. The company has 46 manufacturing facilities for the production of APIs and formulations across various therapeutic categories.

Its products comply with the Medicines and Healthcare Products Regulatory Agency (MHRA), US FDA, Danish Medicines Agency, Health Canada, Federal Ministry of Health, the National Health Surveillance Agency (ANVISA) Brazil, Medicines Control Council (MCC) South Africa, the Colombia National Food and Drug Surveillance Institute (INVIMA), and Australian Government Department of Health. Cipla has a presence in India, the US, Germany, Norway, Spain, the UK, Sri Lanka, South Africa, Australia, and Brazil.

Also, United Biotech Pvt ltd.  (India)designs, develops, creates, and manufactures cutting-edge products and is actively operating in the pharmaceutical industry. Its product assists in developing manufacturing technologies. It offers product categories including oncology drugs, injectables, tablets, syrups, and ointments. The company products are used in a variety of settings including pharmaceutical and biotechnology laboratories, pilot plants, production facilities, and academic research institutions. It provides its products through more than 21 distributors.

### **Key Companies in the India Sickle Cell Anaemia Market include**

- [Cipla Ltd](https://www.cipla.com/press-releases-statements/Roche-Cipla-announce-arrival-of-first-batch-of-antibody-cocktail-drug-Casirivimab-Imdevimab-India) (India)
- United Biotech Pvt Ltd. (India)
- Neon (India)
- [Novartis AG](https://www.novartis.com/news/media-releases/novartis-sickle-cell-medicine-adakveo-approved-europe-prevent-recurrent-vaso-occlusive-crises) (Switzerland)
- Taj Pharmaceuticals Limited. (India)
- Celon Labs (India)
- Salius Pharma Pvt. Ltd (India)
- Pfizer Inc (US)
- Emmaus Medical, Inc (US)
- Teva Pharmaceutical Industries Ltd (Israel)

### **India Sickle Cell Anaemia Industry Developments**

**November 2019:** The U.S. Food and Drug Administration (FDA) has approved Global Blood Therapeutics as a subsidiary of Pfizer's Oxbryta (Voxelotor), the first medicine specifically targeting the root cause of sickle cell disease. The product is distributed throughout India by the company utilizing an online portal and a network of local distributors.

## **India Sickle Cell Anaemia Market Segmentation**

### **India Sickle Cell Anaemia Type Outlook**

- Sickle Cell Anemia (SS)
- Sickle Hemoglobin-C Disease (SC)
- Sickle Beta-Plus Thalassemia
- Sickle Beta-Zero Thalassemia

### **India Sickle Cell Anaemia Diagnosis & Treatment Type Outlook**

## Market Drivers

### Government Initiatives and Policies

The India Sickle Cell Disease Market is witnessing a surge in government initiatives aimed at addressing the challenges posed by sickle cell disease. The Indian government has launched various programs to enhance awareness, screening, and treatment facilities across the country. For instance, the National Health Mission has been instrumental in implementing screening programs in tribal areas, where the prevalence of sickle cell disease is notably high. These initiatives not only aim to improve early diagnosis but also facilitate access to treatment, thereby potentially reducing morbidity and mortality rates associated with the disease. Furthermore, the government's commitment to integrating sickle cell disease management into the broader healthcare framework suggests a long-term strategy to combat this genetic disorder, which could significantly impact the India Sickle Cell Disease Market.

### Technological Advancements in Treatment

The India Sickle Cell Disease Market is benefiting from technological advancements in treatment options, which are becoming increasingly accessible to patients. Innovations such as gene therapy and novel pharmacological agents are emerging as potential game-changers in the management of sickle cell disease. For instance, recent developments in gene editing technologies, like CRISPR, hold promise for curative approaches that could transform patient outcomes. Additionally, the introduction of new medications aimed at reducing pain crises and improving overall quality of life is enhancing treatment paradigms. As these technologies become more integrated into the healthcare system, they are likely to attract investment and research funding, further propelling the growth of the India Sickle Cell Disease Market. The convergence of technology and healthcare is expected to create a more favorable environment for patients and providers alike.

### Rising Prevalence of Sickle Cell Disease

The India Sickle Cell Disease Market is significantly influenced by the rising prevalence of sickle cell disease, particularly in certain regions such as Madhya Pradesh, Maharashtra, and Odisha. Reports indicate that approximately 2-3% of the population in these areas is affected by this genetic disorder, leading to an increased demand for healthcare services and treatment options. This growing prevalence is prompting healthcare providers and policymakers to prioritize sickle cell disease management, thereby creating a more robust market environment. The increasing number of patients necessitates the development of specialized treatment centers and the availability of advanced therapies, which could potentially drive market growth. As awareness about the disease continues to spread, the India Sickle Cell Disease Market is likely to expand further, catering to the needs of a larger patient population.

### Growing Patient Advocacy and Support Groups

The India Sickle Cell Disease Market is increasingly influenced by the emergence of patient advocacy and support groups, which play a vital role in raising awareness and providing resources for affected individuals. These organizations are instrumental in educating the public about sickle cell disease, promoting early diagnosis, and advocating for better healthcare policies. Their efforts are fostering a supportive community that empowers patients and families to seek timely medical intervention. Additionally, these groups often collaborate with healthcare providers to improve access to treatment and support services, thereby enhancing the overall management of the disease. As the presence of these advocacy groups grows, they are likely to contribute to a more informed patient population, which could positively impact the India Sickle Cell Disease Market.

### Increased Focus on Research and Development

The India Sickle Cell Disease Market is experiencing a heightened focus on research and development, which is crucial for advancing treatment options and understanding the disease better. Various academic institutions and pharmaceutical companies are investing in research initiatives aimed at discovering new therapies and improving existing ones. This investment is likely to lead to the development of innovative treatment modalities that could significantly enhance patient care. Moreover, collaborations between public and private sectors are fostering an environment conducive to research, which may yield breakthroughs in the management of sickle cell disease. As the body of knowledge surrounding the disease expands, it is anticipated that the India Sickle Cell Disease Market will evolve, offering more effective solutions to patients and healthcare providers.

## Future Outlook

The India Sickle Cell Disease Market is projected to grow at a 12.22% CAGR from 2025 to 2035, driven by increasing awareness, advancements in treatment, and government initiatives.

**New opportunities:**

- Development of targeted gene therapies for Sickle Cell Disease Expansion of [telehealth](https://www.marketresearchfuture.com/reports/telehealth-market-900) services for remote patient monitoring Investment in community-based screening programs to identify at-risk populations

By 2035, the market is expected to achieve substantial growth, enhancing treatment accessibility and patient outcomes.

## Segment Insights

### By Application: Blood Transfusion (Largest) vs. Gene Therapy (Fastest-Growing)

In the India Sickle Cell Disease Market, the application segments are diversified, with Blood Transfusion holding the largest share, as it is the primary intervention for managing severe anemia and preventing complications. Following closely, Gene Therapy is emerging as a significant player, driven by advancements in research and technology that promise long-term remission from sickle cell disease. Other treatments such as Hydroxyurea Therapy, Pain Management, and Vaccination still play crucial roles but are less dominant in terms of market share.

Growth trends indicate that while Blood Transfusion remains critical, the rapid development and increasing accessibility of Gene Therapy suggest a transformative shift in the treatment landscape for sickle cell disease in India. The governmental support for genetic research and increasing healthcare awareness among populations at risk are significant drivers that will likely fuel the adoption of innovative therapies like Gene Therapy. The market is set to evolve with a growing emphasis on personalized medicine and long-term solutions for patients.

Blood Transfusion (Dominant) vs. Gene Therapy (Emerging)

Blood Transfusion is a well-established and dominant practice in managing sickle cell disease in India, providing immediate relief from symptoms and reducing complications associated with severe anemia. It is a widely accepted treatment protocol, endorsed by healthcare providers across various settings, from hospitals to community clinics. On the other hand, Gene Therapy represents an emerging approach that targets the root cause of sickle cell disease by modifying the patient's genes to produce healthier red blood cells. This innovative treatment is gaining traction, facilitated by ongoing research and clinical trials that highlight its potential for long-term disease management. As awareness grows and technology improves, Gene Therapy is poised to become a cornerstone of future sickle cell disease treatments.

### By Treatment Type: Curative Treatment (Largest) vs. Preventive Treatment (Fastest-Growing)

In the India Sickle Cell Disease Market, the treatment type segment is witnessing a varied distribution of market shares among its segments. Curative Treatment holds the largest share, driven by advancements in gene therapy and hematopoietic stem cell transplantation, which are becoming more accessible due to infrastructure improvements. Preventive Treatment, including strategies like regular blood transfusions and iron chelation therapy, is rapidly gaining attention and constitutes a growing part of the market as efforts to reduce disease incidence intensify.

As the awareness of Sickle Cell Disease and its implications grows, the demand for treatment options has surged. Preventive Treatment is being recognized for its potential to improve patients' quality of life, driving its popularity upward. With increased investments in research and development, both curative and preventive approaches are expected to dominate the landscape, backed by government initiatives and a push for better healthcare solutions.

Curative Treatment (Dominant) vs. Preventive Treatment (Emerging)

Curative Treatment in the India Sickle Cell Disease Market represents a dominant force, primarily focusing on advanced therapeutic approaches such as gene therapy and stem cell transplants. These treatments aim to address the root cause of the disease, providing long-term solutions for affected individuals. On the other hand, Preventive Treatment is emerging as a critical focus area, emphasizing the need for early interventions and consistent management to reduce complications associated with the disease. This segment encompasses methods such as regular health check-ups, blood screening, and management strategies that can significantly improve patient outcomes. The increasing engagement of healthcare providers and NGOs in awareness campaigns showcases the growing importance of both treatment types in combating Sickle Cell Disease.

### By Patient Demographics: Pediatric Patients (Largest) vs. Adult Patients (Fastest-Growing)

In the India Sickle Cell Disease Market, the patient demographic segment is predominantly characterized by pediatric patients, who represent the largest proportion of those affected. These younger patients tend to have a higher prevalence of the disease, often identified at an early age through newborn screening programs. Adult patients, while fewer in number compared to the pediatric cohort, are witnessing a notable increase in diagnoses, attributable to greater awareness and advancements in screening techniques that facilitate earlier detection of sickle cell disease among this age group.
Growth trends indicate a significant shift, with adult patient demographics emerging as the fastest-growing segment in the India Sickle Cell Disease Market. This growth can be linked to heightened awareness about sickle cell disease and its implications, alongside improved access to healthcare and treatment options for adults. Moreover, the rising number of adults being diagnosed underscores a critical public health focus on managing the disease across all age groups, particularly in regions with a known prevalence of sickle cell traits.

Pediatric Patients (Dominant) vs. Adult Patients (Emerging)

Pediatric patients represent the dominant segment in the India Sickle Cell Disease Market, primarily due to the higher incidence of sickle cell disease among children. Early diagnosis through newborn screening has become a cornerstone in managing this genetic disorder, allowing healthcare providers to initiate treatment protocols early. The support structures in place, including specialized clinics and community health programs, cater explicitly to this demographic, ensuring comprehensive care and management. Conversely, adult patients constitute the emerging segment in this market, with an increasing number of cases being identified due to improved awareness and enhanced diagnostic capabilities. This segment faces unique challenges, including the need for tailored treatment options and ongoing management strategies that consider the complexities of adult life, thereby driving a shift in focus towards ensuring quality care for this evolving patient demographic.

### By Diagnosis Method: Blood Tests (Largest) vs. Genetic Testing (Fastest-Growing)

In the India Sickle Cell Disease Market, the Diagnosis Method segment is characterized by a variety of approaches, with Blood Tests holding the largest market share. This method continues to be the conventional choice for disease identification and monitoring, leading to its dominance in this segment. However, Genetic Testing is emerging rapidly, capturing the attention of healthcare providers and patients alike with its precision and the ability to provide genetic insights for families and at-risk populations. As public awareness grows and technology advances, the Genetic Testing segment is expected to see significant growth in the coming years. The increasing emphasis on early diagnosis and preventative healthcare, combined with advancements in genetic technologies, is driving this trend. Newborn Screening is also gaining traction as part of early healthcare initiatives, further diversifying the options available for effective disease management in Sickle Cell Disease.

Blood Tests: (Dominant) vs. Genetic Testing (Emerging)

Blood Tests are regarded as the dominant method for diagnosing Sickle Cell Disease in India, primarily due to their widespread adoption and reliability in providing definitive results. They typically offer immediate outcomes, making them a preferred choice in many clinical settings. In contrast, Genetic Testing represents an emerging trend in the market, leveraging advanced technologies to analyze DNA for accurate carrier status. The increased focus on personalized medicine and family planning is amplifying the relevance of Genetic Testing. While Blood Tests are essential for initial diagnosis, Genetic Testing is paving the way for enhanced prognosis and tailored treatment options, highlighting a shift toward more informed healthcare decisions.

## Competitive Benchmarking

The Sickle Cell Disease Market in India is characterized by a competitive landscape that is increasingly shaped by innovation, strategic partnerships, and regional expansion. Key players such as Bristol Myers Squibb (IN), Novartis (IN), and Roche (IN) are actively engaged in enhancing their operational focus through various strategic initiatives. Bristol Myers Squibb (IN) emphasizes research and development, particularly in gene therapy, which appears to be a pivotal area for future growth. Novartis (IN) is concentrating on expanding its portfolio of therapies, while Roche (IN) is leveraging its strong presence in diagnostics to enhance treatment pathways for patients. Collectively, these strategies indicate a market that is not only competitive but also dynamic, with companies striving to differentiate themselves through innovation and comprehensive patient care solutions.
In terms of business tactics, companies are increasingly localizing manufacturing and optimizing supply chains to enhance efficiency and reduce costs. The market structure is moderately fragmented, with several players vying for market share. However, the influence of major companies is significant, as they set trends in treatment protocols and patient management strategies. This competitive structure suggests that while there is room for smaller players, the dominance of established firms is likely to shape the market's future direction.
In December 2025, Novartis (IN) announced a strategic partnership with a leading Indian biotechnology firm to co-develop a novel gene therapy for Sickle Cell Disease. This collaboration is expected to accelerate the development timeline and enhance access to innovative treatments for patients in India. The strategic importance of this partnership lies in its potential to leverage local expertise and resources, thereby facilitating a more tailored approach to treatment that aligns with regional healthcare needs.
In November 2025, Roche (IN) launched a new diagnostic tool aimed at improving the early detection of Sickle Cell Disease. This tool is designed to streamline the diagnostic process, potentially leading to earlier interventions and better patient outcomes. The introduction of this technology underscores Roche's commitment to integrating diagnostics with treatment, which may enhance its competitive positioning in the market.
In January 2026, Bristol Myers Squibb (IN) revealed plans to invest in a new manufacturing facility in India, aimed at increasing the production capacity of its Sickle Cell Disease therapies. This investment is likely to bolster supply chain reliability and reduce lead times for product availability, which could be a critical factor in meeting the growing demand for effective treatments. The strategic move reflects a broader trend of companies seeking to enhance their operational capabilities in response to market needs.
As of January 2026, current competitive trends in the Sickle Cell Disease Market are increasingly defined by digitalization, sustainability, and the integration of artificial intelligence in treatment protocols. Strategic alliances are becoming more prevalent, as companies recognize the value of collaboration in driving innovation. Looking ahead, it appears that competitive differentiation will evolve from traditional price-based competition to a focus on technological advancements, innovative treatment solutions, and robust supply chain management. This shift may ultimately lead to improved patient outcomes and a more sustainable market environment.

## Recent News & Developments

**November 2019:** The U.S. Food and Drug Administration (FDA) has approved Global Blood Therapeutics as a subsidiary of Pfizer's Oxbryta (Voxelotor), the first medicine specifically targeting the root cause of sickle cell disease. The product is distributed throughout India by the company utilizing an online portal and a network of local distributors.

## Report Scope

| MARKET SIZE 2024 | 0.259(USD Billion) |
| --- | --- |
| MARKET SIZE 2025 | 0.294(USD Billion) |
| MARKET SIZE 2035 | 0.92(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 12.22% (2024 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Billion |
| Key Companies Profiled | Bristol Myers Squibb (IN), Novartis (IN), Pfizer (IN), Roche (IN), Amgen (IN), Boehringer Ingelheim (IN), Sanofi (IN), Celgene (IN), GSK (IN) |
| Segments Covered | Application, Treatment Type, Patient Demographics, Diagnosis Method |
| Key Market Opportunities | Emerging gene therapies and increased awareness drive growth in the India Sickle Cell Disease Market. |
| Key Market Dynamics | Rising awareness and government initiatives are driving advancements in Sickle Cell Disease management in India. |
| Countries Covered | India |

## Frequently Asked Questions

**Q: What is the current valuation of the India Sickle Cell Disease Market?**
A: The market valuation was 0.259 USD Billion in 2024.

**Q: What is the projected market size for the India Sickle Cell Disease Market by 2035?**
A: The projected valuation for 2035 is 0.92 USD Billion.

**Q: What is the expected CAGR for the India Sickle Cell Disease Market during the forecast period?**
A: The expected CAGR from 2025 to 2035 is 12.22%.

**Q: Which companies are the key players in the India Sickle Cell Disease Market?**
A: Key players include Bristol Myers Squibb, Novartis, Pfizer, Roche, Amgen, Boehringer Ingelheim, Sanofi, Celgene, and GSK.

**Q: What are the main applications in the India Sickle Cell Disease Market?**
A: Main applications include Blood Transfusion, Gene Therapy, Hydroxyurea Therapy, Pain Management, and Vaccination.

**Q: How does the market segment by treatment type for Sickle Cell Disease?**
A: The market segments by treatment type include Curative Treatment, Preventive Treatment, Symptomatic Treatment, and Supportive Treatment.

**Q: What demographic segments are considered in the India Sickle Cell Disease Market?**
A: Demographic segments include Pediatric Patients, Adult Patients, Geriatric Patients, and Pregnant Women.

**Q: What diagnosis methods are utilized in the India Sickle Cell Disease Market?**
A: Diagnosis methods include Blood Tests, Genetic Testing, Newborn Screening, and Clinical Evaluation.

**Q: What was the market valuation for Blood Transfusion in 2024?**
A: The market valuation for Blood Transfusion was 0.065 USD Billion in 2024.

**Q: What is the projected market size for Hydroxyurea Therapy by 2035?**
A: The projected market size for Hydroxyurea Therapy is expected to reach 0.3 USD Billion by 2035.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/india-sickle-cell-anaemia-market-22045*